Abstract
Respiratory syncytial virus (RSV) is a dominating respiratory infection worldwide. It is responsible for infecting millions of children worldwide each winter through highly contagious droplets and secretions. Over 2.1 million of these children require some form of medical attention during illness. Due to this high disease burden, the development of new agents to prevent or reduce the spread of RSV has been a top priority. Recently, nirsevimab, a new monoclonal antibody was introduced for the 2023-2024 winter season that holds promise for limiting the spread, morbidity, and mortality associated with RSV.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
